Early Phase Study Aims to Improve OS in HER2+ Breast Leptomeningeal Disease
Kamran A. Ahmed, MD, gives an overview of the phase 1/2 study of radiation therapy followed by intrathecal trastuzumab and pertuzumab in the management of HER2-positive breast leptomeningeal disease.
Kamran A. Ahmed, MD, a radiation oncologist at the Moffitt Cancer Center, gives an overview of the phase 1/2 study of radiation therapy followed by intrathecal trastuzumab (Herceptin) and pertuzumab (Perjeta) in the management of HER2-positive breast leptomeningeal disease.
According to Ahmed, patients with HER2-positive leptomeningeal disease have a poor prognosis and high unmet clinical need. On its own, radiotherapy remains an important treatment strategy for leptomeningeal disease and trastuzumab is an important treatment for HER2-positive breast cancer. According to Ahmed, there is a strong clinical rationale for their combination for the treatment of HER2-positive breast leptomeningeal disease.
The phase 1/2 study has a single arm. After treatment is initiated, patients will receive either 10mg, 20mg, 40mg, or 80mg of pertuzumab. The trastuzumab dose will remain stable. In order to participate, patients must have a life expectancy of at least 8 weeks.
T-DXd Shows Effectiveness in Treating HER2+ Advanced Solid Tumors
April 1st 2024The DESTINY-PanTumor02 trial and the HERALD/EPOC1806 study are showing promising data regarding trastuzumab deruxtecan across several tumor types, including endometrial, cervical, ovarian, bladder, biliary tract, pancreatic, and more.
Read More
Challenges Persist for HCPs and Patients With Breast Cancer
March 1st 2024In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed findings of a quality improvement initiative identifying challenges for health care professionals and patients with HER2-positive breast cancer.
Read More
